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A B S T R A C T
Cardiac resynchronization therapy (CRT) improves symptoms and cardiac function, 
reduces hospitalizations and increases survival in selected patients with heart failure. 
It is mandatory to maximize mechanical and electrical synchronicity. Atrio-ventricu-
lar and ventriculo-ventricular intervals optimization have a substantial impact on the 
hemodynamic response to pacing. The number of patients with an implanted CRT 
system is increasing and many issues have not yet been answered about who and how 
will benefit the most.
I N T R O D U C T I O N
Cardiac resynchronization therapy (CRT) was introduced to improve symptoms, 
exercise capacity and cardiac function, to reduce hospitalizations and to increase 
survival when added to optimal medical treatment in selected patients with refrac-
tory heart failure.1,2 Over the last years, numerous publications have confirmed the 
beneficial role of CRT.3-7 As a consequence, the latest guidelines of the European 
Society of Cardiology for the treatment of heart failure have encompassed this therapy 
as a Class I Level A recommendation, for the treatment of patients with poor clini-
cal performance (NYHA III-IV), low ejection fraction (EF<35%), prolonged QRS 
duration (QRS duration >120 ms).8
Nevertheless, a quarter of these patients with advanced heart failure fail to respond 
to this treatment9,10 based on either clinical or echocardiographic criteria. This pitfall 
of CRT has been attributed to our inability to predict who of the patients with refrac-
tory heart failure may benefit from resynchronization therapy. The criteria for patient 
selection mentioned in the guidelines do not meet the challenge of identifying with a 
high level of confidence the population that will respond to treatment.
P R E D I C T I O N  O F  R E S P O N S E  T O  C R T
Changes in the QRS with pacing do not predict CRT efficacy11 as responders exhibit 
a significant reduction in QRS duration after CRT, but individual responses are highly 
variable and do not permit adequate selection12. QRS duration alone cannot be used 
as an accurate index of parameters that may adversely affect the results of CRT. Some 
of these parameters are: inappropriate patient selection, ischemic vs. non-ischemic 
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ABBREVIATIONS
CRT= Cardiac resynchronization therapy
AV= Atrio-ventricular (interval)
VV= ventriculo-ventricular (between 
ventricles) (interval)
PVARP= Post-ventricular atrial 
refractory period
VTI= Velocity time integral
TDI= Tissue Doppler Imaging
IEGM= intracardiac electrogram
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cardiomyopathy as the cause of heart failure, the presence 
of scar tissue in the failing myocardium, variability in the 
coronary venous anatomy and incorrect lead positioning, or 
the suboptimal device programming over time that may have 
detrimental effect on the outcome of CRT overall.
Some predictors to identify responders to CRT therapy 
have been suggested but until now, there is no echocar-
diographic parameter of dyssynchrony that can be recom-
mended13. Myocardial contractile reserve (>7.5% increase in 
the left ventricular ejection fraction (LVEF) during low-dose 
dobutamine infusion) predicts left ventricular (LV) reverse 
remodeling after CRT14. In a sub-study of the CARE-HF 
trial it was demonstrated that mitral regurgitation and NT-pro 
BNP measured 3 months after intervention, were powerful 
independent predictors of long-term survival15. New evidence 
has shown that change in NT-pro BNP levels from baseline to 3 
months after successful CRT device implantation was a strong 
predictor of long-term response16. A prompt blood pressure 
rise just after resynchronization may also predict short- and 
long-term clinical improvement in CRT recipients.17
Another issue which clearly has not been addressed yet 
is the definition of non-responders to CRT. Definition of 
response vary from functional parameters (such as NYHA 
class, 6 minutes walk test) to reverse left ventricular remod-
eling, morbidity and mortality. Specific criteria on the lack of 
improvement of NYHA, the left ventricular dimensions and 
volumes, the ejection fraction or the cardiac output may all 
have conflicting responses and cause more confusion18.
O P T I M I Z A T I O N  O F  C R T  P R O G R A M M I N G
S I M P L E  PA C E M A K E R  P R O G R A M M I N G
Under the need of managing an increasing population 
with heart failure and in the setting of relative uncertainty 
about who will gain benefit from this therapeutic strategy, it is 
mandatory to optimize mechanical and electrical synchronic-
ity by all the means reported in the literature and applied in 
every day practice so far.
CRT optimization should always start with some common 
pacemaker troubleshooting such as identification of fusion 
and pseudofusion beats, the loss of ventricular capture, the 
percentage estimation of atrial and ventricular pacing, the 
presence of atrial tachyarrhythmias and ventricular premature 
beats and tachyarrythmias, the activation of rate response in 
patients with chronotropic incompetence19, the presence of 
inappropriately long atrio-ventricular (AV) interval and the 
correction of atrial undersensing and ventricular oversens-
ing.
The upper tracking rate should be set to higher values 
than the default 120 beats per minute (bpm), i.e. to 140 -150 
bpm in order to ensure biventricular pacing during rapid heart 
rates with exercise. However, an ultra short post-ventricular 
atrial refractory period (PVARP), may result in pacemaker-
mediated tachycardia or tracking of atrial arrhythmias. Many 
devices have the capability to extend PVARP duration espe-
cially after a premature ventricular contraction in order to 
avoid this phenomenon. Loss of atrial sensing and biventricular 
pacing thereafter, might be a side-effect which has success-
fully been dealt with algorithms that shorten the PVARP e.g., 
Atrial Tracking Recovery™ of Medtronic (Minneapolis, MN, 
USA) or Tracking Preference™ of Guidant (Indianapolis, 
IN, USA) or AVControl™ of Biotronik (Berlin, Germany). 
Automatic mode switching should be enabled in all patients 
since most of them have a history of or will enounter an atrial 
arrhythmia in the future20. Maintenance of left ventricular 
capture should be carefully monitored as plays a crucial role 
in left ventricular function21 keeping in mind that thresholds 
may rise after implantation22. Pacing amplitude and durations 
should be carefully programmed using unipolar and bipolar 
configuration, increase of pulse width, pacing between the 
left and right ring electrodes and automatic measurement 
of left ventricular thresholds. Ventricular sensing is another 
parameter that has to be taken into account in order to avoid 
oversensing of P waves resulting then to inhibition of left 
ventricular pacing when the left ventricular lead is rarely 
implanted in a basal position23. Either reducing the sensitivity 
or programming sensing to a unipolar configuration may help 
oversensing issues.
A D VA N C E D  C R T  O P T I M I Z A T I O N
Atrio-ventricular (AV) interval optimization has been 
used in most clinical trials and may have a substantial impact 
on the hemodynamic response to pacing, affecting the left 
ventricular stroke volume and cardiac output; the optimiza-
tion of AV interval may affect the final outcome either by 
prolonging AV interval in patients with interatrial conduc-
tion delay, or by shortening the AV interval in cases of fusion 
with intrinsic conduction, long PR, or delayed relaxation of 
the left ventricle.
Several techniques have been used so far for optimization 
of AV interval: Echocardiography has been extensively used 
with the aim to separate fused E and A mitral flow waves 
leading to prolongation of diastolic filling time. This has been 
addressed using methods like the Ritter Method, which uses 
one short and one long AV interval and measures the delay 
between the onset of QRS and the end of A wave. The opti-
mal AV interval may be calculated as such: AVopt=AVlong 
– (QAshort – QAlong).24
Simpler method is the simplified mitral inflow method 
measuring once the interval between the end of A wave and 
the onset of mitral regurgitation which then is subtracted 
from the long AV delay.25 Iterative method uses consecutive 
measurements with different AV delays in order to achieve 
the best one.
The aortic velocity time integral (VTI ) using Continuous-
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Wave Doppler and the mitral VTI using Pulse-Wave Doppler 
have also been very helpful to individually optimize AV inter-
vals in several studies although they seem time consuming and 
with relatively low reproducibility. Finger plethysmography 
and Impedance Cardiography are non-echocardiographic 
methods with limited clinical applicability.
The limited reproducibility and the need for special 
equipment have demanded for the development of special 
algorithms of the devices that calculate automatically the AV 
delay based on the QRS width and intrinsic AV intervals. The 
existing algorithms are the Guidant’s Expert Ease for Heart 
Failure™ algorithm26 and the Peak endocardial acceleration 
incorporated in the devices of the Sorin group, (Milan, Italy)27. 
These algorithms although helpful in clinical practice may 
prove insufficient to optimise an actively exercising patient 
with increased heart rates and in need for prolongation of AV 
delay during exercise.
Optimizing the between the two ventricles (VV) interval 
affects interventricular and intraventricular synchrony. Several 
methods have been tried but echocardiographic ones are the 
most broadly applied. Optimization can be done by measur-
ing the aortic Velocity Time Integral (VTI)28 or the highest 
mean global Tissue Doppler Imaging (TDI) velocity of the 
ventricular segments at different VV intervals29. It is recom-
mended that AV optimization be performed first and then be 
followed by VV delay optimization. In most studies the major-
ity of patients have optimal VV intervals with left ventricular 
preexcitation that are within a range of ±20msec. Studies have 
shown superiority of optimized sequential biventricular pacing 
over simultaneous biventricular pacing in short-term outcomes 
such as hemodynamic status, contractility (dP/dt), and tissue 
Doppler changes. Nonetheless, the VV delay optimization 
conferred no additional benefit compared with simultaneous 
biventricular stimulation in NYHA functional class, 6-minute 
hall walk test and quality of life,30 has not improved ventricular 
volumes and systolic function31, has not promoted additional 
reverse remodeling at 6 months and has not increased the 
proportion of echocardiographic responders to CRT.32 So it 
seems prudent to apply VV optimization not to all, but restrict 
it only to non-responders at follow up.
There has been a trend to get away from echo-based 
optimization with some sort of electrogram-based systems 
that can be performed during routine device follow-up. Al-
gorithms have been embedded to the pacemaker software to 
maximize ventricular pacing in atrial tachyarrhythmias like 
the Medtronic Conducted AF Response™ and Biotronik Rate 
Fading™ algorithm.
A study that compared an intracardiac electrogram 
(IEGM) guided optimization and echocardiographic optimi-
zation for cardiac resynchronization in heart failure patients 
with dual-chamber ICD implants demonstrated that the 
concordance correlation coefficient between the values of the 
standard method of aortic VTI measurement and the IEGM 
method aortic VTI values was 97.5%, 96.1%, and 96.6%, re-
spectively.33 An ongoing but not recruiting participants study, 
the Frequent Optimization Study using the QuickOpt34 is 
looking at the efficacy of the QuickOpt™ system, an algorithm 
developed by St Jude Medical Inc (Little Canada, MN, USA) 
based mainly on VV delay modification to optimize CRT with 
an automated repeatedly done optimization based on IEGM 
vs. standard programming of the devices. A recent prospective 
study35 compares echocardiographic and QuickOpt optimiza-
tion and shows that echocardiographic optimization gives a 
superior hemodynamic outcome. Nevertheless it is suggested 
that easier and quicker QuickOpt system could initially be 
applied to all patients with recommended echocardiographic 
optimization to non-responderss.
A second study underway, the Comparison of AV Op-
timization Methods Used in Cardiac Resynchronization 
Therapy (SMART-AV) study,36 is looking again at a more 
comprehensive electrogram-based system for AV optimization 
in a three-arm study, using nominal parameters, echo-based 
optimization, or electrogram-based optimization applying 
the SmartDelay™ algorithm developed by Boston Scientific 
(Natick, MA, USA). The results of this study are expected to 
allow us determine if one mode of optimization is superior 
to the other. It will also demonstrate the magnitude of that 
benefit, both in terms of clinical outcomes to the patient as 
well as magnitude of reverse remodeling.
C O N C L U S I O N S
The number of patients with refractory heart failure is 
steadily increasing. Beyond those who fulfil the classic cri-
teria, patients with QRS duration <120msec or with atrial 
fibrillation with evident mechanical dyssynchrony may also 
benefit from CRT. An increasing number of patients with 
an implanted CRT system develop changes in clinical status, 
with posture, in exercise, have arrhythmias and show differ-
ences in ventricular stress that take place continuously over 
time. The decision when to study an individual, reprogram 
and resynchronize the heart is still an unanswered issue. The 
only certain way to find out who will respond to treatment is 
to try it and go for the best synchronicity over time focusing 
on non-responders and on initially responders who deteriorate 
clinically.
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